Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209279/ https://www.ncbi.nlm.nih.gov/pubmed/25408659 http://dx.doi.org/10.1159/000367966 |
_version_ | 1782341241498763264 |
---|---|
author | Kunzmann, Volker Herrmann, Ken Bluemel, Christina Kapp, Markus Hartlapp, Ingo Steger, Ulrich |
author_facet | Kunzmann, Volker Herrmann, Ken Bluemel, Christina Kapp, Markus Hartlapp, Ingo Steger, Ulrich |
author_sort | Kunzmann, Volker |
collection | PubMed |
description | The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete metabolic remission as measured by integrated fludeoxyglucose ((18)F) positron emission tomography and computerized tomography. After a follow-up of 18 months the patient is alive without progression of disease. We propose to assess the clinical benefit of sequencing the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy for patients with locally advanced and initially unresectable pancreatic cancer in a controlled clinical trial. |
format | Online Article Text |
id | pubmed-4209279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-42092792014-11-18 Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer Kunzmann, Volker Herrmann, Ken Bluemel, Christina Kapp, Markus Hartlapp, Ingo Steger, Ulrich Case Rep Oncol Published online: September, 2014 The prognosis of patients with locally advanced pancreatic cancer can be improved if secondary complete (R0) resection is possible. In patients initially staged as unresectable this may be achieved with neoadjuvant treatment which is usually chemoradiotherapy based. We report the case of a 46-year-old patient with an unresectable, locally advanced pancreatic cancer (pT4 Nx cM0 G2) who was treated with a sequential neoadjuvant chemotherapy regimen consisting of 2 cycles of nab-paclitaxel plus gemcitabine followed by 4 cycles of FOLFIRINOX. Neoadjuvant chemotherapy resulted in secondary resectability (R0 resection). After 2 cycles of nab-paclitaxel plus gemcitabine, the patient already had a complete metabolic remission as measured by integrated fludeoxyglucose ((18)F) positron emission tomography and computerized tomography. After a follow-up of 18 months the patient is alive without progression of disease. We propose to assess the clinical benefit of sequencing the combinations nab-paclitaxel plus gemcitabine and FOLFIRINOX as neoadjuvant therapy for patients with locally advanced and initially unresectable pancreatic cancer in a controlled clinical trial. S. Karger AG 2014-09-18 /pmc/articles/PMC4209279/ /pubmed/25408659 http://dx.doi.org/10.1159/000367966 Text en Copyright © 2014 by S. Karger AG, Basel http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Users may download, print and share this work on the Internet for noncommercial purposes only, provided the original work is properly cited, and a link to the original work on http://www.karger.com and the terms of this license are included in any shared versions. |
spellingShingle | Published online: September, 2014 Kunzmann, Volker Herrmann, Ken Bluemel, Christina Kapp, Markus Hartlapp, Ingo Steger, Ulrich Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title | Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title_full | Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title_fullStr | Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title_full_unstemmed | Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title_short | Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer |
title_sort | intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by folfirinox in a patient with locally advanced unresectable pancreatic cancer |
topic | Published online: September, 2014 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209279/ https://www.ncbi.nlm.nih.gov/pubmed/25408659 http://dx.doi.org/10.1159/000367966 |
work_keys_str_mv | AT kunzmannvolker intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer AT herrmannken intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer AT bluemelchristina intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer AT kappmarkus intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer AT hartlappingo intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer AT stegerulrich intensifiedneoadjuvantchemotherapywithnabpaclitaxelplusgemcitabinefollowedbyfolfirinoxinapatientwithlocallyadvancedunresectablepancreaticcancer |